Psychiatric and non-psychiatric drugs causing false-positive amphetamines urine test in psychiatric patients: a pharmacovigilance analysis using FAERS

References

• Tests for drugs of abuse. Med Lett Drugs Ther. 2002;44(1137):71–73.
   PubMed Web of Science ®Google Scholar
• Armbruster DA, Schwarzhoff RH, Hubster EC, et al. Enzyme immunoassay, kinetic microparticle immunoassay, radioimmunoassay, and fluorescence polarization immunoassay compared for drugs-of-abuse screening. Clin Chem. 1993;39(10):2137–2146. DOI:10.1093/clinchem/39.10.2137
   PubMed Web of Science ®Google Scholar
• Morgan JP. Problems of mass urine screening for misused drugs. J Psychoactive Drugs. 1984;16(4):305–317.
   PubMed Web of Science ®Google Scholar
• Moeller KE, Lee KC, Kissack JC. Urine drug screening: practical guide for clinicians. Mayo Clin Proc. 2008;83(1):66–76.
   PubMed Web of Science ®Google Scholar
• Wilkening GL, Hale GM, Ross C. Urine drug screens: considerations for the psychiatric pharmacist. Ment Health Clin. 2016;6(1):42–47.
   PubMedGoogle Scholar
• Kapur BM, Aleksa K. What the lab can and cannot do: clinical interpretation of drug testing results. Crit Rev Clin Lab Sci. 2020 [cited 2022 Nov 25];57:548–585. https://www.tandfonline.com/doi/full/10.1080/10408363.2020.1774493
   PubMed Web of Science ®Google Scholar
• Drevets WC, Gautier C, Price JC, et al. Amphetamine-induced dopamine release in human ventral striatum correlates with euphoria. Biol Psychiatry. 2001;49(2):81–96. DOI:10.1016/S0006-3223(00)01038-6
   PubMed Web of Science ®Google Scholar
• Clydon C, Sweeney J, Blakey P National drug strategy household survey 2019. 2020 [cited 2022 Nov 25]; Available from: https://www.aihw.gov.au/reports/illicit-use-of-drugs/national-drug-strategy-household-survey-2019/contents/table-of-contents.
   Google Scholar
• Dadlani N, Farrar A, Jones G. Variability amongst urine toxicology amphetamine readings with concurrent administration of fenofibrate. Australas Psychiatry. 2018;26(1):24–26.
   PubMed Web of Science ®Google Scholar
• Brown H, Pollard KA. Drugs of Abuse: sympathomimetics. Crit Care Clin. 2021;37(3):487–499.
   PubMed Web of Science ®Google Scholar
• Poyatos L, Torres A, Papaseit E, et al. Abuse potential of cathinones in humans: a systematic review. JCM. [cited 2023 Mar 21]. 2022;11:1004. InternetAvailable from. 4. https://www.mdpi.com/2077-0383/11/4/1004
   Google Scholar
• Grant BF, Stinson FS, Dawson DA, et al. Prevalence and co-occurrence of substance use disorders and independent mood and anxiety disorders: results from the national epidemiologic survey on alcohol and related conditions. Arch Gen Psychiatry. 2004;61(8):807–816. DOI:10.1001/archpsyc.61.8.807
   PubMed Web of Science ®Google Scholar
• Hunt GE, Large MM, Cleary M, et al. Prevalence of comorbid substance use in schizophrenia spectrum disorders in community and clinical settings, 1990-2017: systematic review and meta-analysis. Drug Alcohol Depend. 2018;191:234–258.
   PubMed Web of Science ®Google Scholar
• Martinez-Raga J, Szerman N, Knecht C, et al. Attention deficit hyperactivity disorder and dual disorders. Educational needs for an underdiagnosed condition. Int J Adolesc Med Health. 2013;25(3):231–243. DOI:10.1515/ijamh-2013-0057
   PubMedGoogle Scholar
• Hofvander B, Ståhlberg O, Nydén A, et al. Life History of Aggression scores are predicted by childhood hyperactivity, conduct disorder, adult substance abuse, and low cooperativeness in adult psychiatric patients. Psychiatry Res. 2011;185(1–2):280–285. DOI:10.1016/j.psychres.2010.05.008
   PubMed Web of Science ®Google Scholar
• Mauri MC, Cirnigliaro G, Piccoli E, et al. Substance abuse associated with aggressive/violent behaviors in psychiatric outpatients and related psychotropic prescription. Int J Ment Health Addiction. 2022 [[cited 2023 Mar 21]; Available from]. Internet: https://link.springer.com/10.1007/s11469-022-00842-w
   Web of Science ®Google Scholar
• Mauri MC, Cirnigliaro G, Di Pace C, et al. Aggressiveness and violence in psychiatric patients: a clinical or social paradigm? CNS Spectr. [cited 2023 Mar 21]. 2019;24:564–573. InternetAvailable from. 5. https://www.cambridge.org/core/product/identifier/S1092852918001438/type/journal_article
   PubMed Web of Science ®Google Scholar
• Caricasole V, Spagnolo G, Di Bernardo I, et al. Aripiprazole causing false positive urine amphetamine drug screen in an adult patient with bipolar disorder. Compr Psychiatry. 2019;94:152126. doi:10.1016/j.comppsych.2019.152126.
   PubMed Web of Science ®Google Scholar
• Sakaeda T, Tamon A, Kadoyama K, et al. Data mining of the public version of the FDA adverse event reporting system. Int J Med Sci. 2013;10:796–803. doi:10.7150/ijms.6048.
   PubMed Web of Science ®Google Scholar
• Carnovale C, Mazhar F, Pozzi M, et al. A characterization and disproportionality analysis of medication error related adverse events reported to the FAERS database. Expert Opin Drug Saf. 2018;17:1161–1169.
   PubMed Web of Science ®Google Scholar
• Carnovale C, Mosini G, Gringeri M, et al. Interaction between paracetamol and lamotrigine: new insights from the FDA adverse event reporting system (FAERS) database. Eur J Clin Pharmacol. 2019;75(9):1323–1325. DOI:10.1007/s00228-019-02691-4
   PubMed Web of Science ®Google Scholar
• Carnovale C, Tombetti E, Battini V, et al. Inflammasome Targeted Therapy in Pregnancy: new Insights from an Analysis of Real-World Data from the FAERS Database and a Systematic Review. Front Pharmacol. 2020;11:612259.
   PubMed Web of Science ®Google Scholar
• Mazhar F, Pozzi M, Gentili M, et al. Association of hyponatraemia and antidepressant drugs: a pharmacovigilance–pharmacodynamic assessment through an analysis of the US Food and Drug Administration adverse event reporting system (FAERS) database. CNS Drugs. 2019;33(6):581–592. DOI:10.1007/s40263-019-00631-5
   PubMed Web of Science ®Google Scholar
• U.S. Department of Health and Human Services Food and Drug Administration. FDA Adverse Event Reporting System (FAERS) Quarterly Data Extract Files [Internet]. https://fis.fda.gov/extensions/FPD-QDE-FAERS/FPD-QDE-FAERS.html. [cited 2022 Nov 25]. Available from: https://fis.fda.gov/extensions/FPD-QDE-FAERS/FPD-QDE-FAERS.html.
   Google Scholar
• The R Foundation [Internet]. [cited 2022 Nov 25]. Available from: https://www.r-project.org/foundation/.
   Google Scholar
• Adashek JJ, Khadilkar A, Enciso J, et al. A case of esmolol-induced false-positive amphetamine urine drug test. Cureus. 2021;13:e12429.
   PubMed Web of Science ®Google Scholar
• Apple FS, Googins MK, Kastner S, et al. Labetalol: false-positive indices by EMIT-d.a.u. assay and Toxi-Lab a urine screen. Clin Chem. 1985;31(7):1250–1251. DOI:10.1093/clinchem/31.7.1250
   PubMed Web of Science ®Google Scholar
• Curtin LB, Cawley MJ. Immunoassay cross-reactivity of phenylephrine and methamphetamine. Pharmacotherapy. 2012;32(5):e98–102.
   PubMed Web of Science ®Google Scholar
• Fenderson JL, Stratton AN, Domingo JS, et al. Amphetamine positive urine toxicology screen secondary to atomoxetine. Case Rep Psychiatry. 2013;2013:381261.
   PubMedGoogle Scholar
• Fucci N. False positive results for amphetamine in urine of a patient with diabetes mellitus. Forensic Sci Int. 2012;223(1–3):e60.
   PubMed Web of Science ®Google Scholar
• Gilbert RB, Peng PI, Wong D. A labetalol metabolite with analytical characteristics resembling amphetamines. J Anal Toxicol. 1995;19(2):84–86.
   PubMed Web of Science ®Google Scholar
• Kaplan YC, Erol A, Karadaş B. False-positive amphetamine/ecstasy (MDMA/3,4-methylenedioxymethamphetamine) (CEDIA) and ecstasy (MDMA/3,4-methylenedioxymethamphetamine) (DRI) test results with fenofibrate. Ther Drug Monit. 2012;34(5):493–495.
   PubMed Web of Science ®Google Scholar
• Kaplan J, Shah P, Faley B, et al. Case reports of aripiprazole causing false-positive urine amphetamine drug screens in children. Pediatrics. 2015;136:e1625–1628.
   PubMed Web of Science ®Google Scholar
• Leclercq M, Soichot M, Delhotal-Landes B, et al. False positive amphetamines and 3,4-methylenedioxymethamphetamine immunoassays in the presence of metoprolol—two cases reported in clinical toxicology. J Anal Toxicol. 2020;44(2):200–205. DOI:10.1093/jat/bkz051
   PubMed Web of Science ®Google Scholar
• Nixon AL, Long WH, Puopolo PR, et al. Bupropion metabolites produce false-positive urine amphetamine results. Clin Chem. 1995;41(6):955–956. DOI:10.1093/clinchem/41.6.955
   PubMed Web of Science ®Google Scholar
• Olsen KM, Gulliksen M, Christophersen AS. Metabolites of chlorpromazine and brompheniramine may cause false-positive urine amphetamine results with monoclonal EMIT d.a.u. immunoassay. Clin Chem. 1992;38(4):611–612.
   PubMed Web of Science ®Google Scholar
• Quesada L, Gomila I, Fe A, et al. Fenofibric acid can cause false-positive urine methylenedioxymethamphetamine immunoassay results. J Anal Toxicol. 2015;39(9):734–740. DOI:10.1093/jat/bkv074
   PubMed Web of Science ®Google Scholar
• Schmolke M, Hallbach J, Guder WG. False-positive results for urine amphetamine and opiate immunoassays in a patient intoxicated with perazine. Clin Chem. 1996;42(10):1725–1726.
   PubMed Web of Science ®Google Scholar
• Snozek CLH, Kaleta EJ, Jannetto PJ, et al. False-positive amphetamine results on several drug screening platforms due to mexiletine. Clin Biochem. 2018;58:125–127.
   PubMed Web of Science ®Google Scholar
• Sohal S, Sous M, Pethe G, et al. Mexiletine and false positive urine drug screen for amphetamine: a case review. Case Rep Med. 2021;2021:7134394.
   PubMed Web of Science ®Google Scholar
• Vidal C, Skripuletz T. Bupropion interference with immunoassays for amphetamines and LSD. Ther Drug Monit. 2007;29(3):373–375.
   PubMed Web of Science ®Google Scholar
• Yee LM, Wu D. False-positive amphetamine toxicology screen results in three pregnant women using labetalol. Obstet Gynecol. 2011;117(2):503–506.
   PubMed Web of Science ®Google Scholar
• Baron JM, Griggs DA, Nixon AL, et al. The trazodone metabolite meta-chlorophenylpiperazine can cause false-positive urine amphetamine immunoassay results. J Anal Toxicol. 2011;35(6):364–368. DOI:10.1093/anatox/35.6.364
   PubMed Web of Science ®Google Scholar
• Bugier S, Garcia-Hejl C, Vest P, et al. A cross-reactivity of fenofibric acid with MDMA DRI assay. Mil Med. 2016;181(9):1013–1015. DOI:10.7205/MILMED-D-15-00442
   PubMed Web of Science ®Google Scholar
• Casey ER, Scott MG, Tang S, et al. Frequency of false positive amphetamine screens due to bupropion using the Syva EMIT II immunoassay. J Med Toxicol. 2011;7(2):105–108. DOI:10.1007/s13181-010-0131-5
   PubMedGoogle Scholar
• Crane T, Dawson CM, Tickner TR. False-positive results from the Syva EMIT d.a.u. monoclonal amphetamine assay as a result of antipsychotic drug therapy. Clin Chem. 1993;39(3):549.
   Web of Science ®Google Scholar
• Hughey JJ, Colby JM. Discovering cross-reactivity in urine drug screening immunoassays through large-scale analysis of electronic health records. Clin Chem. 2019;65(12):1522–1531.
   PubMed Web of Science ®Google Scholar
• Liu L, Wheeler SE, Rymer JA, et al. Ranitidine interference with standard amphetamine immunoassay. Clin Chim Acta. 2015;438:307–308.
   PubMed Web of Science ®Google Scholar
• Lora-Tamayo C, Tena T, Rodríguez A, et al. High concentration of chloroquine in urine gives positive result with Amphetamine CEDIA reagent. J Anal Toxicol. 2002;26(1):58. DOI:10.1093/jat/26.1.58
   PubMed Web of Science ®Google Scholar
• Manzi S, Law T, Shannon MW. Methylphenidate produces a false-positive urine amphetamine screen. Pediatr Emerg Care. 2002;18(5):401.
   PubMed Web of Science ®Google Scholar
• Melanson SEF, Lee-Lewandrowski E, Griggs DA, et al. Reduced interference by phenothiazines in amphetamine drug of abuse immunoassays. Arch Pathol Lab Med. 2006;130(12):1834–1838. DOI:10.5858/2006-130-1834-RIBPIA
   PubMed Web of Science ®Google Scholar
• Reidy L, Walls HC, Steele BW. Crossreactivity of bupropion metabolite with enzyme-linked immunosorbent assays designed to detect amphetamine in urine. Ther Drug Monit. 2011;33(3):366–368.
   PubMed Web of Science ®Google Scholar
• Marin SJ, Doyle K, Chang A, et al. One hundred false-positive amphetamine specimens characterized by liquid chromatography time-of-flight mass spectrometry. J Anal Toxicol. 2016;40:37–42.
   PubMed Web of Science ®Google Scholar
• Chan K-H, Hsu M-C, Tseng C-Y, et al. Famprofazone use can be misinterpreted as methamphetamine abuse. J Anal Toxicol. 2010;34(6):347–353. DOI:10.1093/jat/34.6.347
   PubMed Web of Science ®Google Scholar
• Cody JT, Valtier S, Nelson SL. Amphetamine enantiomer excretion profile following administration of Adderall. J Anal Toxicol. 2003;27(7):485–492.
   PubMed Web of Science ®Google Scholar
• Greenhill B, Valtier S, Cody JT. Metabolic profile of amphetamine and methamphetamine following administration of the drug famprofazone. J Anal Toxicol. 2003;27(7):479–484.
   PubMed Web of Science ®Google Scholar
• Kraemer T, Wennig R, Maurer HH. The antispasmodic drug mebeverine leads to positive amphetamine results by fluorescence polarization immunoassay (FPIA)—studies on the toxicological analysis of urine by FPIA and GC-MS. J Anal Toxicol. 2001;25(5):333–338.
   PubMed Web of Science ®Google Scholar
• Wijngaard R, Parra-Robert M, Marés L, et al. Tetracaine from urethral ointment causes false positive amphetamine results by immunoassay. Clin Toxicol (Phila). 2021;59(6):500–505. DOI:10.1080/15563650.2020.1834114
   PubMed Web of Science ®Google Scholar
• Pope JD, Drummer OH, Schneider HG. False-positive amphetamines in urine drug screens: a 6-year review. J Anal Toxicol. 2023;47(3):263–270.
   PubMed Web of Science ®Google Scholar
• Saitman A, Park H-D, Fitzgerald RL. False-positive interferences of common urine drug screen immunoassays: a review. J Anal Toxicol. 2014;38(7):387–396. doi:10.1093/jat/bku075.
   PubMed Web of Science ®Google Scholar
• Vincent EC, Zebelman A, Goodwin C, et al. Clinical inquiries. What common substances can cause false positives on urine screens for drugs of abuse? J Fam Pract. 2006;55(10):893–894, 897.
   PubMed Web of Science ®Google Scholar
• Ayala-Lopez N, Colby JM, Hughey JJ. Analysis of electronic health records reveals medication-related interference on point-of-care urine drug screening assays. J Anal Toxicol. 2022;46(1):99–102.
   PubMed Web of Science ®Google Scholar
• Vorce SP, Holler JM, Cawrse BM, et al. Dimethylamylamine: a drug causing positive immunoassay results for amphetamines. J Anal Toxicol. 2011;35(3):183–187. DOI:10.1093/anatox/35.3.183
   PubMed Web of Science ®Google Scholar
• Winek CL, Kuhlman JJ, Shanor SP. Detection and interference of some central nervous system stimulants in urine drug-screening procedures. Clin Toxicol. 1980;17(2):337–351.
   PubMed Web of Science ®Google Scholar
• Poklis A, Jortani SA, Brown CS, et al. Response of the Emit II amphetamine/methamphetamine assay to specimens collected following use of Vicks inhalers. J Anal Toxicol. 1993;17(5):284–286. DOI:10.1093/jat/17.5.284
   PubMed Web of Science ®Google Scholar
• Krasowski MD, Siam MG, Iyer M, et al. Chemoinformatic methods for predicting interference in drug of abuse/toxicology immunoassays. Clin Chem. 2009;55(6):1203–1213. DOI:10.1373/clinchem.2008.118638
   PubMed Web of Science ®Google Scholar
• Petrie M, Lynch KL, Ekins S, et al. Cross-reactivity studies and predictive modeling of “Bath Salts” and other amphetamine-type stimulants with amphetamine screening immunoassays. Clin Toxicol (Phila). 2013;51(2):83–91. DOI:10.3109/15563650.2013.768344
   PubMed Web of Science ®Google Scholar
• Mazhar F, Battini V, Pozzi M, et al. Hyponatremia following antipsychotic treatment: in silico pharmacodynamics analysis of spontaneous reports from the US Food and Drug Administration Adverse Event Reporting System Database and an updated systematic review. Int J Neuropsychopharmacol. 2021;24(6):477–489. DOI:10.1093/ijnp/pyab005
   PubMed Web of Science ®Google Scholar
• Pellegrino P, Carnovale C, Perrone V, et al. On the association between human papillomavirus vaccine and primary ovarian failure. Am J Reprod Immunol. 2014;71(4):293–294. DOI:10.1111/aji.12190
   PubMed Web of Science ®Google Scholar
• Kessler RC, Berglund P, Demler O, et al. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA. 2003;289:3095–3105.
   PubMed Web of Science ®Google Scholar
• Klassen LJ, Bilkey TS, Katzman MA, et al. Comorbid attention deficit/hyperactivity disorder and substance use disorder: treatment considerations. Curr Drug Abuse Rev. 2012;5(3):190–198. DOI:10.2174/1874473711205030190
   PubMedGoogle Scholar
• Kale N. Urine Drug Tests: ordering and Interpreting Results. Am Fam Physician. 2019;99(1):33–39.
   PubMedGoogle Scholar
• Levy S, Siqueira LM, On Substance Abuse C, et al. Testing for drugs of abuse in children and adolescents. Pediatrics. 2014;133(6):e1798–1807. DOI:10.1542/peds.2014-0865
   PubMed Web of Science ®Google Scholar
• Smith ML, Nichols DC, Underwood P, et al. Methamphetamine and amphetamine isomer concentrations in human urine following controlled Vicks VapoInhaler administration. J Anal Toxicol. 2014;38(8):524–527. DOI:10.1093/jat/bku077
   PubMed Web of Science ®Google Scholar
• Romberg RW, Needleman SB, Snyder JJ, et al. Methamphetamine and amphetamine derived from the metabolism of selegiline. J Forensic Sci. 1995;40(6):1100–1102. DOI:10.1520/JFS13885J
   PubMed Web of Science ®Google Scholar
• Stahl SM. Stahl’s essential psychopharmacology: neuroscientific basis and practical applications. UK: Cambridge university press; 2021.
   Google Scholar
• Komossa K, Depping AM, Meyer M, et al. Second-generation antipsychotics for obsessive compulsive disorder. Cochrane Database Syst Rev. 2010; CD008141. DOI:10.1002/14651858.CD008141.pub2.
   Web of Science ®Google Scholar
• Logan BK, Costantino AG, Rieders EF, et al. Trazodone, meta-chlorophenylpiperazine (an hallucinogenic drug and trazodone metabolite), and the hallucinogen trifluoromethylphenylpiperazine cross-react with the EMIT®II ecstasy immunoassay in urine. J Anal Toxicol. 2010;34(9):587–589. DOI:10.1093/jat/34.9.587
   PubMed Web of Science ®Google Scholar
• Geffen J, Forster K. Treatment of adult ADHD: a clinical perspective. Ther Adv Psychopharmacol. 2018;8(1):25–32.
   PubMed Web of Science ®Google Scholar
• Perugi G, Pallucchini A, Rizzato S, et al. Current and emerging pharmacotherapy for the treatment of adult attention deficit hyperactivity disorder (ADHD). Expert Opin Pharmacother. 2019;20(12):1457–1470. DOI:10.1080/14656566.2019.1618270
   PubMed Web of Science ®Google Scholar
• McCann BS, Simpson TL, Ries R, et al. Reliability and validity of screening instruments for drug and alcohol abuse in adults seeking evaluation for attention-deficit/hyperactivity disorder. Am J Addict. 2000;9(1):1–9. DOI:10.1080/10550490050172173
   PubMed Web of Science ®Google Scholar
• Dupouy J, Mémier V, Catala H, et al. Does urine drug abuse screening help for managing patients? A systematic review. Drug Alcohol Depend. 2014;136:11–20.
   PubMed Web of Science ®Google Scholar
• Faillie J-L. Case–non-case studies: principle, methods, bias and interpretation. Therapie. 2019;74(2):225–232.
   PubMed Web of Science ®Google Scholar
• Christo PJ, Manchikanti L, Ruan X, et al. Urine drug testing in chronic pain. Pain Physician. 2011;14(2;3):123–143. DOI:10.36076/ppj.2011/14/123
   PubMed Web of Science ®Google Scholar
• Vandevenne M, Vandenbussche H, Verstraete A. Detection time of drugs of abuse in urine. Acta Clin Belg. 2000;55(6):323–333.
   PubMed Web of Science ®Google Scholar
• Rengarajan A, Mullins ME. How often do false-positive phencyclidine urine screens occur with use of common medications? Clin Toxicol (Phila). 2013;51(6):493–496.
   PubMed Web of Science ®Google Scholar
• Carnovale C, Lucenteforte E, Battini V, et al. Association between the glyco-metabolic adverse effects of antipsychotic drugs and their chemical and pharmacological profile: a network meta-analysis and regression. Psychol Med. 2021;52(15):1–13. DOI:10.1017/S0033291721000180
   Web of Science ®Google Scholar
• Galal A, El-Bakly WM, El-Kilany SS, et al. Fenofibrate ameliorates olanzapine’s side effects without altering its central effect: emphasis on FGF-21–adiponectin axis. Behav Pharmacol. 2021;32(8):615–629. DOI:10.1097/FBP.0000000000000656
   PubMed Web of Science ®Google Scholar